Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CCNI
REST API REST API
Homo sapiens
CCNI is differentially expressed in 272 experiments: 134 organism parts: liver, cerebellum, ... (132 more);, 187 disease states: normal, cervical carcinoma, ... (185 more);, 68 cell types 365 cell lines 33 compound treatments and 76 other conditions.
Orthologs F6UA53_CIOIN (Ciona intestinalis)   A4FUE4_BOVIN (Bos taurus)   Ccni (Rattus norvegicus)   F1P1K0_CHICK (Gallus gallus)   CycG (Drosophila melanogaster)   Ccni (Mus musculus)   ccni (Danio rerio)   ccni (Xenopus laevis)   CCNI (Canis familiaris)   (Compare orthologs)
InterPro Term Cyclin-like, Cyclin_N
Gene Ontology Term spermatogenesis
UniProt Accession D6RDK3, D6RH01, D6RG12, D6REZ3, Q14094, B7Z6X4
Search EB-eye ENSG00000118816
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-7540, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
BT-474
2
E-GEOD-3529, E-GEOD-5823
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
359 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-13987, ... (39 experiments)

Factor Value U/D Experiments
2
E-TABM-145, E-TABM-130
CD4+ T cell
2
E-GEOD-16190, E-AFMX-5
mononuclear
1
E-GEOD-26672
basal cell
1
E-GEOD-3998
spheroid
1
E-GEOD-4219
CD33+ myeloid
1
E-AFMX-5
62 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-MEXP-1121, E-TABM-15, E-GEOD-16363, ... (53 experiments)

Factor Value U/D Experiments
cervical carcinoma
4
E-MTAB-62, E-MEXP-1331, E-GEOD-5823, E-MTAB-37
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
colon carcinoma
2
E-MTAB-62, E-MTAB-37
glioblastoma
2
E-GEOD-4290, E-GEOD-6014
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
melanoma
2
E-MTAB-62, E-MTAB-37
181 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-MEXP-941, ... (25 experiments)

Factor Value U/D Experiments
N-nitrosodimethylamine
1
E-GEOD-6907
dimethyl sulfoxide
1
E-GEOD-5824
control for heregulin
1
E-GEOD-6462
unknown
1
E-GEOD-7307
4,5-dianilinophthalimide
1
1
E-GEOD-5258
AMP
1
E-MEXP-2285
27 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
41
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-22541, E-GEOD-2509, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847 ... (5 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-18736, E-TABM-601, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-6432, E-GEOD-5681, E-GEOD-12773, E-TABM-127, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-1956, E-MEXP-2069, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-MEXP-1082, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19136, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, E-GEOD-6532 ... (5 experiments)

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.252 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM